

IC20 Rec'd PCT/PTO 29 SEP 2005

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

Date Submitted to PTO: September 29, 2005

ATTY DOCKET NO.
2005_1543ASERIAL NO.
NEW

10/551138

APPLICANT
Dimitrios E. LIZOS et al.FILING DATE
September 29, 2005

GROUP

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
BJD	AA	3,539,631	11/1970	Pallos et al.			
	AB						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
BJD	AC	99/04778	2/1999	WO				
I	AD	96/29316	9/1996	WO				
I	AE	0 011 182	5/1980	EP				X
	AF							
	AG							

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

BJD	AH	Database Registry, Chemical Abstracts Service, April 12, 1986, Chemical Abstracts: RN 101398-76-9, XP002287521, Abstract.
I	AI	Frank P. Bymaster et al., "Unexpected antipsychotic-like activity with the muscarinic receptor ligand (5R,6R)6-(3-propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1]octane", European Journal of Pharmacology, Vol. 356, No. 2-3, September 4, 1998, pp. 109-119.
I	AJ	S. M. Cochran et al., "Induction of differential patterns of local cerebral glucose metabolism and immediate-early genes by acute clozapine and haloperidol", Neuropharmacology, Vol. 43, No. 3, September 2002, pp. 394-407.
I	AK	B. Pouzet et al., "Effects of the 5-HT ₂ receptor antagonist SB-258741 in animal models for schizophrenia", Pharmacology, Biochemistry and Behavior, Vol. 71, No. 4, April 2002, pp. 655-665.
	AL	
	AM	

EXAMINER

DATE CONSIDERED

10/15/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.